anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GOAL: To address healthcare spending growth, coordinate care, and improve primary care utilization, a majority of states in the United States have adopted value-based care coordination programs. The objective of this study was to identify changes in national healthcare utilization for children with developmental disabilities (DDs), a high-cost and high-need population, following the broad adoption of value-based care coordination policies.
METHODS: This retrospective study included 9,109 children with DDs and used data from 2002-2018 Medical Expenditure Panel Survey. We applied an interrupted time series design approach to compare pre- and post-Affordable Care Act (ACA) care coordination policies concerning healthcare utilization outcomes, including outpatient visits, home provider days, emergency department (ED) visits, inpatient discharge, and inpatient nights of stay.
PRINCIPAL FINDINGS: We found statistically significant increases in low-cost care post-ACA, including outpatient visits (5% higher, p < .001) and home provider days (11% higher, p < .001). The study findings also showed a statistically significant increase in inpatient nights of stay post-ACA (4% higher, p = .001). There were no changes in the number of ED and inpatient visits. Overall, broad implementation of care coordination programs was associated with increased utilization of low-cost care without increases in the number of high-cost ED and inpatient visits for children with DDs. Our study also found changes in population composition among children with DDs post-ACA, including increases in Hispanic (16.9% post-ACA vs. 13.4% pre-ACA, p = .006) and non-Hispanic multiracial children (9.1% post-ACA vs. 5.5% pre-ACA, p = .001), a decrease in non-Hispanic Whites (60.2% post-ACA vs. 68.6% pre-ACA, p = .001), more public-only insurance (44.3% post-ACA vs. 35.7% pre-ACA, p = .001), fewer children with DDs from middle-income families (27.4% post-ACA vs. 32.8% pre-ACA, p < .001), and more children with DDs from poor families (28.2% post-ACA vs. 25.1% pre-ACA, p = .043).
PRACTICAL APPLICATIONS: These findings highlight the importance of continued support for broad care coordination programs for U.S. children with DDs and potentially others with complex chronic conditions. Policymakers and healthcare leaders might consider improving care transitions from inpatient to community or home settings by overcoming barriers such as payment models and the lack of home care nurses who can manage complex chronic conditions. Healthcare leaders also need to understand and consider the changing population composition when implementing care coordination-related policies. This study provides data regarding trends in hospital and home care utilization and evidence of the effectiveness of care coordination policies before the COVID-19 interruption. These findings apply to current healthcare management because COVID-19 has incentivized home care, which may have a strong potential to minimize high-cost care for people with complex chronic conditions. More research is warranted to continue monitoring care coordination changes over a longer period.
The incidence and mortality of chronic kidney disease (CKD) are increasing globally. Studies have demonstrated the significance of genetic risk factors in the progression of CKD. Telomerase reverse transcriptase (TERT) may be implicated in the development of CKD. This study aimed to investigate the correlation between TERT gene variants and susceptibility to CKD in the Chinese population. A total of 507 patients with CKD and 510 healthy controls were recruited for this case-control study. Four candidate loci were identified using the MassARRAY platform. Logistic regression analysis was employed to assess the association between TERT gene variants and the risk of CKD. The false positive reporting probability (FPRP) method was utilized to evaluate the validity of statistically significant associations. The multifactorial dimensionality reduction (MDR) method was used to evaluate the interaction between SNPs and the risk of CKD. Furthermore, discrepancies in the clinical features of subjects with diverse genotypes were evaluated using one-way analysis of variance (ANOVA). Our findings revealed a correlation between rs2735940 and rs4635969 and an increased risk of CKD. Stratification analysis indicated that rs4635969 was related to an increased risk of CKD in different subgroups (age ≤ 50 years and male). MDR analysis indicated that the two-site model (rs2735940 and rs4635969) was the best prediction model. Furthermore, the rs2735940 GG genotype was found to be linked to an increased level of microalbuminuria (MAU) in patients with CKD. Our study is the first to reveal a connection between TERT gene variants and susceptibility to CKD, providing new insights into the field of nephrology.
BACKGROUND: Gait classification is a clinically helpful task performed after a stroke in order to guide rehabilitation therapy. Gait disorders are commonly identified using observational gait analysis in clinical settings, but this approach is limited due to low reliability and accuracy. Data-driven gait classification can quantify gait deviations and categorise gait patterns automatically possibly improving reliability and accuracy; however, the development and clinical utility of current data driven systems has not been reviewed previously.
RESEARCH QUESTION: The purpose of this systematic review is to evaluate the literature surrounding the methodology used to develop automatic gait classification systems, and their potential effectiveness in the clinical management of stroke-affected gait.
METHOD: The database search included PubMed, IEEE Xplore, and Scopus. Twenty-one studies were identified through inclusion and exclusion criteria from 407 available studies published between 2015 and 2022. Development methodology, classification performance, and clinical utility information were extracted for review.
RESULTS AND SIGNIFICANCE: Most of gait classification systems reported a classification accuracy between 80%-100%. However, collated studies presented methodological errors in machine learning (ML) model development. Further, many studies neglected model components such as clinical utility (e.g., predictions don't assist clinicians or therapists in making decisions, interpretability, and generalisability). We provided recommendations to guide development of future post-stroke automatic gait classification systems to better assist clinicians and therapists. Future automatic gait classification systems should emphasise the clinical significance and adopt a standardised development methodology of ML model.
PURPOSE:To make the anticoagulant easy to dissolve in water, by a method wherein a polymer obtained by radical polymerization of a specified unsaturated carboxylic acid is modified by amine or converted into alkali metal or an alkaline earth metal salt and then, after the separation of the polymer, it is dissolved into water again to be made freeze-dry. CONSTITUTION:A fatty or aromatic unsaturated carboxylic acid with 1-20C is subjected to a radical polymerization. The polymer thus obtained is modified by fatty or aromatic mono-, di- or triamine with 1-20C or converted into an alkali metal salt or alkaline earth metal salt. Then, after the separation and refining of the polymer, it is dissolved into water to be made freeze-dry and granulated. For example, acrylic acid is polymerized, the resulting polymer is modified by ethylendiamine or converted into a sodium salt by sodium hydroxide and the polymer is dissolved into water again to be made freeze-dry and granular. Thus, as made freeze-dry and granular, this high molecular blood anticoagulant can be made easy to dissolve in water and excellent in the blood solubility and moreover, can prevent changes in red blood cells or the like.
The present invention relates to methods of reducing the effects of neuropathically induced negative sensory phenomena (NSP). NSP are manifested as the decreased ability to feel light touch, pain, proprioception, vibration, warm/heat, and coolness/cold. The NSP are treated by application of an anesthetic. The anesthetic is preferably a benzoic acid-based anesthetic.  Specifically, a patch containing about 5% lidocaine may be used. The anesthetic is transdermally administered to a patient suffering from NSP at or near the locus of the negative sensory phenomena.
The invention discloses a taraxane-type triterpene and a preparation method and application thereof. The taraxane-type triterpenes are specifically 6 compounds separated from Sapium discolor (Champ. ex Benth.) Muell. Arg.). The tests of the applicant show that the taraxane-type triterpene compound can obviously inhibit the release of BV2 microglia NO stimulated by LPS under the condition of not influencing the survival rate of BV2 microglia, particularly the inhibition effect of the compound 5 and the compound 6 is obviously superior to that of minocycline which is a clinically commonly used drug, has better potential medicinal value, and is expected to be used for preparing neurodegenerative disease drugs.
Two year carcinogenicity studies with pramipexole have been conducted in mice and rats. Pramipexole was administered in the diet to Chbb:NMRI mice at doses of 0.3, 2, and 

10 mg/kg/day [0.3, 2.2, and 11 times the maximum recommended human dose [MRHD of 1.5 mg TID on a mg/m2 basis). Pramipexole was administered in the diet to Wistar rats at 0.3, 2, and 8 mg/kg/day (plasma AUCs were 0.3, 2.5, and 12.5 times the AUC in humans at the MRHD). No significant increases in tumors occurred in either species. 

Pramipexole was not mutagenic or clastogenic in a battery of assays, including the in vitro Ames assay, V79 gene mutation assay for HGPRT mutants, chromosomal aberration assay in Chinese hamster ovary cells, and in vivo mouse micronucleus assay.

In rat fertility studies, pramipexole at a dose of 2.5 mg/kg/day (5 times the MRHD on a mg/m2 basis), prolonged estrus cycles and inhibited implantation. These effects were associated with reductions in serum levels of prolactin, a hormone necessary for implantation and maintenance of early pregnancy in rats.
Health care providers may lack data-driven guidance about best practises for discussing weight. We assessed women's self-perception of body mass index (BMI) and preferences for weight counselling by provider characteristics and the initiating question. A voluntary, anonymous survey was completed by 756 women (age ≥ 19 year) at our tertiary care obstetrics and gynaecology clinics in autumn 2021. The respondents' height and weight were collected before respondents selected graphics from a validated Body Image Scale that they felt best represented their current body size and which graphs should prompt weight loss or gain recommendations. Respondents were asked their preferences about provider characteristics for discussion about weight and to identify which of six initiating questions from a provider was most and least preferred. Blank responses were allowed. In 708 responses, 366 women (52%) selected the most accurate graphic that corresponded to their BMI; the selected graphic represented a lower than actual BMI in 268 women (38%) and higher in 74 women (10%). In 648 responses, 374 women (58%) preferred a female provider, but provider body shape, ethnicity/race and age were not important to most women. The most preferred question to initiate a discussion about weight was "A lot of women have trouble achieving or maintaining a healthy weight; is that something we can discuss?" in 181 of 555 women (33%), and the least preferred question was "Do you feel like you are at an appropriate weight?" in 172 of 554 women (31%). Provider knowledge about patient preferences regarding questions may facilitate the discussion about weight.
The invention discloses a traditional Chinese medicine fumigation method for rehabilitation, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine for rehabilitation comprises folium artemisiae argyi, scallop, donkey-hide gelatin, angelica, rhizoma cyperi, radix linderae, honeysuckle, radix rehmanniae preparata, mint, chicory root and liquorice. The invention can well mix several kinds of powder by using the electromagnetic field to replace a mechanical vibration field, and improves the mixing degree and the solubility in water to ensure that the powder reaches a paramagnetic state. The invention adopts a vortex separation mode for separation, and linear motion is converted into circular motion under the action of centrifugal force, so that the separation efficiency is improved. The invention can improve the recovery speed of the patient to a great extent, reduce the pain after the operation and has low recurrence rate. The postoperative recovery date of the female is 20-24 days, the cure cases are 45-47 persons, the effective cases are 2-3 persons, the effective rate reaches 94% -98%, and the curative effect is stable.
In a two-year time period (2011 to 2012) 443 patients of suspected of disc herniation and risk of low work ability - based on questionnaires participated in a randomized control trial. The patients were randomized to either the intervention group (n=220) or control group (n=223). The intervention group were invited to the Department of Social Medicine two to four weeks after their first contact to Department of Rheumatology for a consultation with a physician specialized in social medicine. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. Throughout the intervention, the patients received their usual treatment from the Department of Rheumatology like patients from the control group. Outcome was return to the work force at one year follow up using information from a national registry.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having an inhibitory action on transformation growth factor β, useful for treating chronic glomerular nephritis, renal interstitial fibrosis, diabetic nephropathy, hepatocirrhosis, etc., by making the inhibitor include ursolic acid (salt) as an active ingredient. SOLUTION: This inhibitor contains ursolic acid (salt) of the formula as an active ingredient. Ursolic acid is contained in leaves and fruits of persimmon, Crataegus cuneata, apple, etc., can be obtained from these plants by extraction/ separation and purification and is sold on the market. An alkaline (earth) metal salt, an organic basic salt including a basic amino acid salt, etc., may be cited as the ursolate. When the inhibitor is used as medicine, a dose as ursolic acid is preferably about 0.01-1,000 mg and administered dividedly twice or three times daily in the case of adult. The inhibitor can be used as an oral medicine such as tablet, syrup, etc., and as an external preparation such as ointment, etc., or an injection, etc.
PCT No. PCT/EP91/02415 Sec. 371 Date Jun. 17, 1993 Sec. 102(e) Date Jun. 17, 1993 PCT Filed Dec. 16, 1991 PCT Pub. No. WO92/11213 PCT Pub. Date Sep. 7, 1991.A method of treating photographic effluent containing one or more metal ions with an oxidation number greater than one, comprising the addition of a water-soluble silicate to the effluent in an amount to render it glass-like and less permeable to water. Conveniently the effluent has been treated by the addition of calcium hydroxide and the silicate, preferably water-glass may then be added either to the treated effluent suspension and the mixture separated or to the pre-separated solid.
This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia \<1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
Thoracentesis is performed by 4 methods: gravity, manual aspiration, vacuum-bottle suction, and wall suction. This literature review investigates the safety of these techniques and determines if there is significant difference in complication rates. A comprehensive literature search revealed 6 articles studying thoracentesis techniques and their complication rates, reviewing 20,815 thoracenteses: 80 (0.4%) by gravity, 9431 (45.3%) by manual aspiration, 3498 (16.8%) by vacuum-bottle suction, 7580 (36.4%) by wall suction and 226 (1.1%) unspecified. Of the 6 studies, 2 were smaller with 100 and 140 patients respectively. Overall, there was a 4.4% complication rate including hemothoraces, pneumothoraces, re-expansion pulmonary edema (REPE), chest discomfort, bleeding at the site, pain, and vasovagal episodes. The pneumothorax and REPE rate was 2.5%. Sub-analyzed by each method, there was a 47.5% (38/80) complication rate in the gravity group, 1.2% (115/9431) in the manual aspiration group including 0.7% pneumothorax or REPE, 8% (285/3498) in the vacuum-bottle group including 3.7% pneumothorax or REPE, 4% (309/7580) in the wall suction group all of which were either pneumothorax or REPE, and 73% (166/226) in the unspecified group most of which were vasovagal episodes. Procedure duration was less in the suction groups versus gravity drainage. The 2 smaller studies indicated that in the vacuum groups, early procedure termination rate from respiratory failure was significantly higher than non-vacuum techniques. Significant complication rate from thoracentesis by any technique is low. Suction drainage was noted to have a lower procedure time. Symptom-limited thoracentesis is safe using vacuum or wall suction even with large volumes drained. Other factors such as procedure duration, quantity of fluid removed, number of needle passes, patients' BMI, and operator technique may have more of an impact on complication rate than drainage modality. All suction modalities of drainage seem to be safe. Operator technique, attention to symptom development, amount of fluid removed, and intrapleural pressure changes may be important in predicting complication development, and therefore, may be useful in choosing which technique to employ. Specific drainage modes and their complications need to be further studied.
PURPOSE: A composition containing a Salvia miltiorrhiza extract, a fraction thereof, or a compound is provided to suppress 3CL protease activity, and to prevent and treat coronavirus infection. CONSTITUTION: A pharmaceutical composition for preventing or treating coronavirus infection contains a Salvia miltiorrhiza extract or a fraction thereof as an active ingredient. The extract is prepared using water, C1-C4 alcohols, or a mixture thereof. The fraction is a hexane fraction, an ethyl acetate fraction, or a water fraction. The pharmaceutical composition contains a compound as an active ingredient, among compounds of chemical formulas 1-7. A method for preventing or treating corona virus infection comprises a step of administering the compound to mammals exclusive of human.
A synthetic nutritional composition comprises milk fat globule membrane (MFGM) in the range of about 10 µg/100 kcal to about 1500 mg/100kcal for use in improving neurological development in a paediatric subject. The synthetic nutritional composition is administered to the paediatric subject for at least three months during the first year of life and administration of the synthetic nutritional composition improves neurological development of the paediatric subject from at least two years of age. The administration of the composition may take place for at least six months during the first year of life. Preferably, the improvement in neurological development is an improvement in cognitive development, such as development of memory, verbal comprehension, visual spatial ability, fluid reasoning, mental processing speed, rule learning, executive function and language acquisition. The improvement may persist until at least five years of age. The MFGM may be provided in an enriched milk product.
The invention discloses a composite traditional Chinese medicine lozenge which has effects of clearing away heat and toxic materials and relieving swelling and stopping pain, as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine preparations. The composite traditional Chinese medicine lozenge consists of the following components in percentage by weight: 4-10% of a Chinese violet extract, 1-5% of a dandelion extract and 85-95% of medicinal auxiliary materials. The invention further discloses a method for preparing the composite traditional Chinese medicine lozenge. The method comprises main processes of preparing the Chinese violet extract, preparing the dandelion extract and preparing the composite traditional Chinese medicine lozenge. In addition, the invention further discloses application of the composite traditional Chinese medicine lozenge in preparing a medicine for treating pharyngitis. Compared with a preparation for treating pharyngitis in the market, the composite traditional Chinese medicine lozenge disclosed by the invention is concise and special in medicinal effect, can treat both symptoms and root causes and is good in specificity as the medicine is retained at focuses of throats for a long time and the medicinal effects can be brought into play rapidly and continuously; meanwhile, by adopting the oral lozenge, the first pass effect of livers can be avoided, and the bioavailability can be high.
The primary component of the interpretation bias manipulation is the Word Sentence Association Paradigm (WSAP) delivered by the HabitWorks smartphone app. Users complete 50 trials in each exercise (approximately 5 min) and are prompted to complete 3 exercises per week (12 total over 4 weeks). The WSAP incorporates repetitive and quick practice, increasing individuals' awareness of their cognitive biases and shifting of their automatic responses.
This study was an open-label (patients and investigators knew what treatment was being given), randomized (patients were assigned to a treatment group by chance) study of lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma patients. This study addressed the clinical and patient-management consequences of treating mild to moderate anemia (hemoglobin (Hb) between 10 and 12 g/dL). The design of the study compared the effect of treating higher Hb levels to current standard of care criteria on Hb levels, transfusion requirements, and patient reported outcomes (quality of life, health care resource utilization, and productivity). Patients were randomized according to their Hb levels. Two entry criteria were specified during the course of the trial. Initially, patients were enrolled with Hb levels \>= 11 g/dL and then randomized to receive 1) Immediate epoetin alfa treatment or 2) Observed after Hb levels fell below 11 g/dL. Epoetin alfa treatment was provided to the Observed group if and when Hb levels fell below 9.0 g/dL. Slow recruitment of patients in to the study resulted in a protocol amendment. Subsequently, if a patient presented with a Hb between 10 and 12 g/dL, the patient was randomized to the Immediate or to the Observed groups. Patients presenting with Hgb \> 12 g/dL but otherwise eligible, were not randomized until Hb dropped to \<=12 g/dL. Patients remained in the study for up to 36 weeks. Safety assessments were performed throughout the study and included obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. The starting dose of PROCRIT (Epoetin alfa) was administered subcutaneously (sc) as 40,000 Units (U) once weekly (qw). If after 3-4 weeks of therapy, the Hb did not increase by \> 1.0 g/dL, the dose was increased to 60,000 U sc qw. If at any time, the Hb rose above 15 g/dL on 2 consecutive evaluations, PROCRIT (Epoetin alfa) was stopped until the Hb dropped to below 13 g/dL and then resumed.